Perspectives on EGFR-mutant and wildtype NSCLC Tailoring treatment advances in late-stage disease - touchONCOLOGY
touchCLINICAL PERSPECTIVES for touchONCOLOGY
Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.